ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
(NasdaqGM:AVBP), NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) — ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share […]